Full Press Release Details
SANUWAVE Hires Shri Parikh as President for Global Healthcare
SUWANEE, GA, JUNE 4, 2018 - SANUWAVE Health, Inc. (OTCQB:
SNWV) is excited to announce that Shri Parikh has joined
SANUWAVE Health effective May 31, 2018 as President of our
Healthcare division. Shri most recently joins us from Molnlycke
Health Care where he held the title of Vice President, Sales and
Marketing. Prior to Molnlycke, Shri was the Director of National
Accounts at Stryker, a leading medical technology company with
products and services in Orthopaedics, Medical and Surgical
Equipment, and Neurotechnology and Spine. Shri began his
career in sales at Bristol-Myers Squibb and held various roles with
increasing sales, marketing and corporate accounts responsibility
at Guidant and St. Jude Medical before joining
are thrilled that Shri chose to join the SANUWAVE family. His
leadership, ethics and commercialization expertise will further
spearhead the design of a carefully thought out go-to market
strategy among other growth management initiatives as we continue
to develop partnerships around the globe, said Chief
Executive Officer, Kevin Richardson who further stated, We
enthusiastically look forward to returning more value to our
shareholders under Shri's direction.
Shri Parikh also commented, stating, I am honored to join
the SANUWAVE team and excited about our future. SANUWAVE's
unparalleled innovative technology and clinical evidence has far
reaching implications benefiting patients suffering from diabetic
foot ulcers and beyond. I look forward to working with the talented
team at SANUWAVE to deliver sustainable capabilities and scale to
support our global growth and commercialization plans, while taking
all the necessary steps to enhance value for all
was born and raised in Charlotte, NC. He holds a Bachelor of Arts
degree in Medical Ethics and Economics from Davison College, a
Master of Business Administration from Jacksonville University and
an Advanced Management Program degree from the University of
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com)
is a shock wave technology company initially focused on the
development and commercialization of patented noninvasive,
biological response activating System for the repair and
regeneration of skin, musculoskeletal tissue and vascular
structures. SANUWAVE's portfolio of regenerative medicine
products and product candidates activate biologic signaling and
angiogenic responses, producing new vascularization and
microcirculatory improvement, which helps restore the body's
normal healing processes and regeneration. SANUWAVE applies its
technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead
product candidate for the global wound care market,
is US FDA cleared for the treatment of Diabetic Foot Ulcers.
System is also CE Marked throughout
Europe and has license approval for the treatment of the skin and
subcutaneous soft tissue in Canada, South Korea, Australia and New
Zealand. SANUWAVE researches, designs, manufactures, markets and
services its products worldwide, and believes it has demonstrated
that its technology is safe and effective in stimulating healing in
chronic conditions of the foot (plantar fasciitis) and the elbow
(lateral epicondylitis) through its U.S. Class III PMA approved
as well as stimulating bone and chronic tendonitis regeneration in
the musculoskeletal environment through the utilization of its
in Europe, Asia and Asia/Pacific. In addition, there are
license/partnership opportunities for SANUWAVE's shock wave
technology for non-medical uses, including energy, water, food and
Forward-Looking Statements
This press release may contain forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995, such as statements relating to
financial results and plans for future business development
activities, and are thus prospective. Forward-looking statements
include all statements that are not statements of historical fact
regarding intent, belief or current expectations of the Company,
its directors or its officers. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, many of which are
beyond the Company's ability to control. Actual results may
differ materially from those projected in the forward-looking
statements. Among the key risks, assumptions and factors that may
affect operating results, performance and financial condition are
risks associated with the regulatory approval and marketing of the
Company's product candidates and products, unproven
pre-clinical and clinical development activities, regulatory
oversight, the Company's ability to manage its capital
resource issues, competition, and the other factors discussed in
detail in the Company's periodic filings with the Securities
and Exchange Commission. The Company undertakes no obligation to
update any forward-looking statement.
For additional information about the Company, visit